2. Academic Validation
  3. In Vitro Antimycobacterial Activity Evaluation of a New Lead Compound (LQFM326) against Clinical Strains of Mycobacterium sp

In Vitro Antimycobacterial Activity Evaluation of a New Lead Compound (LQFM326) against Clinical Strains of Mycobacterium sp

  • ACS Omega. 2025 Aug 26;10(35):39875-39883. doi: 10.1021/acsomega.5c04174.
Tracy M M Martins 1,  Luciano M Lião 2,  Gerlon A R Oliveira 3,  Pedro E A Silva 4,  Ana J Reis 4,  Yasmin C Neves 4,  Glaura R C C Lima 5,  Beatriz S Gontijo 6,  José R do Carmo Neto 6,  Jonathas X Pereira 6,  André Kipnis 7,  Ricardo Menegatti 8
Affiliations

Affiliations

  • 1 Federal University of Pará, Faculty of Medicine, Center for Morphological Studies (NEM-ATM), 68372-040 Altamira, PA, Brazil.
  • 2 Federal University of Goiás, Institute of Chemistry, Nuclear Magnetic Resonance Laboratory (LabRMN), 74690-900 Goiânia, GO, Brazil.
  • 3 University of Brasília, Department of Pharmacy, Faculty of Health Sciences, 70910-900 Brasília, DF, Brazil.
  • 4 Federal University of Rio Grande, Faculty of Medicine, Laboratory of Mycobacteria, 96203-900 Rio Grande, RS, Brazil.
  • 5 Medical Biology of Central Public Health Laboratory of the Federal District, 70830-010 Brasília, DF, Brazil.
  • 6 Federal University of Goiás, Institute of Tropical Pathology and Public Health, Cellular and Molecular Pathology Laboratory, 74690-900 Goiânia, GO, Brazil.
  • 7 Federal University of Goiás, Institute of Tropical Pathology and Public Health, Molecular Bacteriology Laboratory, 74690-900 Goiânia, GO, Brazil.
  • 8 Federal University of Goiás, Faculty of Pharmacy, Laboratory of Medicinal Pharmaceutical Chemistry (LQFM), 74001-970 Goiânia, GO, Brazil.
PMID: 40949240 DOI: 10.1021/acsomega.5c04174
Abstract

Tuberculosis (TB) remains a significant global public health challenge. The novel compound LQFM326 was evaluated for its antimycobacterial activity against seven Mycobacterium species. Minimum inhibitory concentrations (MICs) were determined, revealing values of 15.6 μg/mL against Mycobacterium tuberculosis H37Ra and 12.5 μg/mL against clinical strains. The MIC values observed for these reference antimicrobials against M. tuberculosis H37Ra were 0.25 μg/mL for rifampicin and 0.125 μg/mL for isoniazid. Surface damage to Mycobacterium abscessus cells was observed via scanning electron microscopy (SEM), confirming morphological alterations induced by LQFM326. Cellular viability was assessed using the Live/Dead assay, with a CC50 of 126.68 ± 42.66 μg/mL. The selectivity index (SI), calculated from MIC and CC50 values, ranged from 2.03 to 10.13, with values above 10 indicating favorable selectivity. Additionally, synergistic effects were observed when LQFM326 was combined with Other Antibiotics. These findings highlight LQFM326 as a promising antimycobacterial agent with potential efflux-inhibitory and synergistic properties. Further studies are needed to validate its efficacy across diverse clinical strains and to elucidate its mechanism of action.

Figures
Products